SiliconInvestor
     Advanced Search   [ sign in ]

register
Sponsor		  register
Register

 Biotech / Medical : Provectus Pharmaceuticals Inc.

 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  
To: NTTG who wrote (8891)5/24/2011 9:10:32 AM
From: pvct investorRead Replies (1) of 11979
 
Of course they're "substantial." But I wasn't referring to what you think of them, rather what they are on paper.

Nevertheless, in your post 8886, I do agree that the MM P3 trial design features will be important, for several reasons. What are your views on the comparatives that should be used for the PV-10 MM P3 trial?
Report TOU ViolationShare This Post
 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQ
Copyright © 1995-2013 Knight Sac Media. All rights reserved.